Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

450.97 +0.60 (+0.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
Got $500? 1 Biotech Stock to Buy and Hold Forever
Via The Motley Fool
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Regulators are reviewing what could become a multi-billion-dollar drug. 
Via The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points
Meta just forged a new base. All five stocks are on the IBD Leaderboard list. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Both stocks have made significant breakthroughs. 
Via The Motley Fool
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes for the 47th president. 
Via Benzinga
5 Top Stocks to Buy in November
From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look. 
Via The Motley Fool
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
The sky's the limit for these stocks. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
Vertex Pharmaceuticals beat third-quarter expectations on Monday. The company also raised its sales outlook. 
Via Investor's Business Daily
Vertex Reports Third Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?
The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday. 
Via Benzinga
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend. 
Via Benzinga
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
It won't be able to be profitable without hitting its targets for both of these figures. 
Via The Motley Fool
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added. 
Via Benzinga
Vertex to Participate in Upcoming November Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?
A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Smartest Growth Stock to Buy With $500 Right Now
This stock might not be available for under $500 for long. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback